TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31578954
Drug: elvitegravir (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: elvitegravir (150 mg), cobicistat (150 mg), emtricitabine (200 mg), and tenofovir alafenamide (10 mg) daily
Study: 31578954
Drug: tenofovir disoproxil
Normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tenofovir disoproxil fumarate (300 mg)
Study: 23698590
Drug: +45T>G SNP,
Approvals — FDA: no, EMA: no, PMDA: no
Description: +45T>G SNP, GG subjects
Study: 19634823
Drug: Augmentation plate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmentation plate fixation with or without autogenous cancellous bone graft
Study: 16702888
Drug: Olanzapine 10
Normalized name: olanzapine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine 10 mg/d or more (n = 120)
Study: 16702888
Drug: Risperidone 3
Normalized name: risperidone 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone 3 mg/d or more (n = 115)
Study: 8985298
Drug: Lamivudine 300
Normalized name: lamivudine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamivudine 300 mg daily
Study: 8107547
Drug: Iron supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplementation (100 mg.d-1)
Study: 27526120
Drug: MP4CO (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: MP4CO (15 mg/kg/dose to 172 mg/kg/dose, single IV doses; two cohorts received fractionated doses of 172 or 344 mg/kg)
Study: 20537746
Drug: Vildagliptin 50mg
Normalized name: vildagliptin
DrugBank: Vildagliptin (DB04876)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Vildagliptin 50mg twice-daily
Study: 16149743
Drug: Formula fortified
Normalized name: S-M-A Iron Formula Fortified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formula fortified with NT at 34 mg/L
Study: 16149743
Drug: Control formula
Normalized name: Anti Acne Control Formula Top
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control formula with an innate level of NT at 10 mg/L
Study: 10565626
Drug: Isotretinoin treatment
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isotretinoin treatment for 30 days
Study: 1651857
Drug: Clinical criteria
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical criteria (CC) and manual evaluation of TOF
Study: 1651857
Drug: Clinical criteria
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical criteria (CC) only
Study: 7034669
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy and occupational therapy in the stroke unit
Study: 7034669
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy and occupational therapy in medical units
Study: 31256761
Drug: Plan C
Normalized name: Plan B One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Plan C (standard rapid rehydration using Ringer's lactate 100 ml/kg over 3 hours, incorporating 0.9% saline boluses for children with shock)
Study: 31256761
Drug: Slow rehydration
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow rehydration (100 ml/kg Ringer's lactate over 8 hours without boluses)
Study: 30095637
Drug: Inhaled ipratropium
Normalized name: ipratropium Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled ipratropium bromide/salbutamol sulfate (COM)
Study: 24821196
Drug: Intranasal ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal ketamine hydrochloride (50 mg)
Study: 17667569
Drug: IgE for
Normalized name: IG
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgE for morphine
Study: 17667569
Drug: ROC analysis
Normalized name: Chemicals and reagents for analysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: ROC analysis for morphine
Study: 16401960
Drug: Hypofractionated radiotherapy
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypofractionated radiotherapy (13 fractions, 3.0 Gy per fraction, and 4 fractions at 4.5 Gy per fraction, total dose of 57 Gy)
Study: 16401960
Drug: Conventional radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional radiotherapy (37 fractions, 2.0 Gy per fraction, total dose of 74 Gy)
Study: 16401960
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (not specified treatment, but included in the study)
Study: 10613619
Drug: 100‐mg enteric‐coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100‐mg enteric‐coated diclofenac tablets
Study: 10613619
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g acetaminophen plus 60 mg codeine
Study: 10613619
Drug: 100‐mg enteric‐coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100‐mg enteric‐coated diclofenac tablets plus 1 g acetaminophen
Study: 10613619
Drug: 100‐mg enteric‐coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100‐mg enteric‐coated diclofenac tablets plus 1 g acetaminophen plus 60 mg codeine
Study: 7864704
Drug: Ciprofloxacin 250
Normalized name: ciprofloxacin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 250 mg BID for 7 days
Study: 7864704
Drug: Ciprofloxacin 100
Normalized name: ciprofloxacin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 100 mg BID for 3 days
Study: 7864704
Drug: Ciprofloxacin 250
Normalized name: ciprofloxacin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 250 mg BID for 3 days
Study: 7864704
Drug: Ciprofloxacin 500
Normalized name: ciprofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 500 mg once daily for 3 days
Study: 7864704
Drug: Ciprofloxacin 500
Normalized name: ciprofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 500 mg once daily for 5 days
Study: 7864704
Drug: Norfloxacin 400
Normalized name: norfloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norfloxacin 400 mg BID for 7 days
Study: 9058224
Drug: 2 mL
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mL of 0.25% bupivacaine
Study: 26714202
Drug: SSRI treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSRI treatment (escitalopram or sertraline)
Study: 26714202
Drug: SNRI treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: SNRI treatment (venlafaxine)
Study: 23650968
Drug: Intranasal fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intranasal fentanyl spray (INFS) 200 μg/100 μl
Study: 23650968
Drug: Oral transmucosal
Normalized name: Thrive, 2 mg oral transmucosal gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral transmucosal fentanyl citrate (OTFC) 200 µg
Study: 18256417
Drug: Saccharomyces boulardii
Normalized name: Saccharomyces boulardii
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saccharomyces boulardii for five days in addition to oral rehydration solution (ORS)
Study: 1336356
Drug: Type I,
Normalized name: Collagen Type I, Bovine
DrugBank: Bovine type I collagen (DB10771)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type I, insulin‐dependent diabetic subjects with microalbuminuria
Study: 1336356
Drug: Normoalbuminuric type
Normalized name: collagen type I
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normoalbuminuric type I, insulin‐dependent diabetic subjects
Study: 2866786
Drug: Bucindolol 50,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bucindolol 50, 100 and 200 mg
Study: 2866786
Drug: Oxprenolol 40,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxprenolol 40, 80 and 160 mg
Study: 16981899
Drug: 500 microg
Normalized name: Etizolam 500 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 microg of intravenous beclomethasone monopropionate (17-BMP) for 15 min
Study: 16981899
Drug: 500 microg
Normalized name: Etizolam 500 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 microg of intravenous beclomethasone monopropionate (17-BMP) for 2 h
Study: 14712987
Drug: Oral conjugated
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral conjugated equine oestrogen, 0.625 mg/day
Study: 14712987
Drug: Transdermal oestradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal oestradiol patches, 50 microg/day
Study: 14712987
Drug: No hormones
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No hormones
Study: 10737822
Drug: Mandatory urine
Normalized name: Urin DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mandatory urine drug screening
Study: 8855811
Drug: Estradiol replacement
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol replacement therapy (micronized estradiol [Estrace TM], 2 mg orally each day)
Study: 8855811
Drug: Estradiol replacement
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol replacement therapy (in subset with less than 3 months of amenorrhea)
Study: 8855811
Drug: No therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No therapy (in subset with greater than 3 months of amenorrhea)
Study: 6379570
Drug: Intravenous cefamandole,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cefamandole, 1.5 g before incision followed by 1.5 g every four hours up to the 24th postoperative hour
Study: 6379570
Drug: No antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibiotic (control group K-)
Study: 31045590
Drug: Curcumin (3000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin (3000 mg/d)
Study: 28626868
Drug: 0.2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/kg meperidine
Study: 28626868
Drug: 2 ml
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ml of normal saline (Control)
Study: 21242793
Drug: Enhanced cleaning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced cleaning of the near-patient environment (twice-daily for 2 months)
Study: 18271889
Drug: Saffron 30
Normalized name: SAFFRON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saffron 30 mg/day (15 mg twice a day; morning and evening)
Study: 17192685
Drug: Sanazole biweekly
Normalized name: Gynazole-1
DrugBank: Butoconazole (DB00639)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sanazole biweekly 1.25 g intravenous infusion 15 minutes before radiotherapy
Study: 14578723
Drug: Restricted intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restricted intravenous fluid regimen
Study: 14578723
Drug: Standard intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard intravenous fluid regimen
Study: 8969353
Drug: EMLA cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA cream (2.5% lidocaine, 2.5% prilocaine) applied 1 hour before phlebotomy
Study: 1472142
Drug: Garlic powder
Normalized name: Garlic Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Garlic powder preparation (900 mg daily for 6 weeks)
Study: 1472142
Drug: Garlic powder
Normalized name: Garlic Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Garlic powder preparation
Study: 26570994
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (omega-3) 3 g/day, taken 3 times a day for 90 days
Study: 26570994
Drug: Mineral oil
Normalized name: Mineral Oil
DrugBank: Mineral oil (DB11057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mineral oil (placebo) 3 g/day, taken 3 times a day for 90 days
Study: 23442582
Drug: Killed whole-virus
Normalized name: INFLUENZA A VIRUS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Killed whole-virus HIV vaccine
Study: 23442582
Drug: Therapeutic HBV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic HBV vaccine
Study: 23442582
Drug: New tuberculosis
Normalized name: Mycobacterium tuberculosis
Approvals — FDA: no, EMA: no, PMDA: no
Description: New tuberculosis vaccine candidate
Study: 23442582
Drug: MenB vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MenB vaccine Bexsero
Study: 19845667
Drug: 4% niacinamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% niacinamide + 2% NAG in SPF 15 sunscreen moisturizing lotion and evening moisturizing cream (test formulation)
Study: 19845667
Drug: Vehicle control
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle control (SPF 15 lotion and cream vehicles)
Study: 16639484
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) 15 mg/weekly + salazopyrin 2 g/daily
Study: 16639484
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) 15 mg/weekly + infliximab 3 mg/Kg at time 0, 2, 4 and every 8 weeks
Study: 16639484
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) 15 mg/weekly + etanercept 25 mg/twice weekly
Study: 16639484
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) 15 mg/weekly + adalimumab 40 mg/every other week
Study: 11834533
Drug: Atorvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (20 mg per day for 4 months)
Study: 9892883
Drug: Propantheline (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propantheline (15 mg)
Study: 2076384
Drug: Pindolol (0.015
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol (0.015 mg/kg intravenously)
Study: 2076384
Drug: Atenolol (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (0.1 mg/kg intravenously)
Study: 2076384
Drug: Atenolol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (50 mg/day orally)
Study: 2076384
Drug: Pindolol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol (10 mg/day orally)
Study: 2076384
Drug: Atenolol (intravenous)
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atenolol (intravenous)
Study: 2076384
Drug: Pindolol (intravenous)
Normalized name: Pindolol
DrugBank: Pindolol (DB00960)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pindolol (intravenous)
Study: 2076384
Drug: Atenolol (oral)
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atenolol (oral)
Study: 2076384
Drug: Pindolol (oral)
Normalized name: Pindolol
DrugBank: Pindolol (DB00960)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pindolol (oral)
Study: 7361794
Drug: Rectal thiopental
Normalized name: thiopental Rectal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal thiopental (25-45 mg/kg)
Study: 7361794
Drug: Intramuscular cocktail
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular cocktail (2.0 mg/kg meperidine, 1.0 mg/kg chlorpromazine, 1.0 mg/kg promethazine)
Study: 25579006
Drug: Superior joint
Normalized name: Astaxanthin/Hyaluronic Acid/Krill Oil Oral Capsule, Liquid Filled [MEGARED SUPERIOR JOINT CARE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Superior joint space injection of hyaluronic acid (HA)
Study: 25579006
Drug: Inferior joint
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inferior joint space injection of hyaluronic acid (HA)
Study: 24952864
Drug: ADRC treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADRC treatment
Study: 19164343
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg montelukast
Study: 19164343
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of desloratadine and montelukast
Study: 17907854
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for Adolescents with Depression Study (TADS)
Study: 8549577
Drug: Continuous contractions
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous contractions (CC) - 30 seconds with 1-minute rest
Study: 2108885
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg leuprorelin acetate depot
Study: 2108885
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg leuprorelin acetate depot
Study: 2108885
Drug: 3.75 mg,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.75 mg, 7.5 mg, and 15 mg leuprorelin acetate depot
Study: 518076
Drug: Control (other
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (other antibiotics, n=30)
Study: 30846896
Drug: IUD plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: IUD plus a new crosslinked hyaluronan (NCH) gel
Study: 30846896
Drug: NCH gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: NCH gel only
Study: 19843321
Drug: XanGo Juice
Normalized name: mango juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: XanGo Juice 18 oz twice daily
Study: 19843321
Drug: XanGo Juice
Normalized name: mango juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: XanGo Juice 3 oz twice daily
Study: 19843321
Drug: XanGo Juice
Normalized name: mango juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: XanGo Juice 6 oz twice daily
Study: 9032592
Drug: IPM/CS monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: IPM/CS monotherapy
Study: 9032592
Drug: IPM/CS combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: IPM/CS combination therapy
Study: 9032592
Drug: IPM/CS combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: IPM/CS combination therapy with other antibiotics (not penicillins, cephalosporins, or aminoglycosides)
Study: 1523286
Drug: Diazepam (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (15 or 20 mg orally)
Study: 1523286
Drug: Lorazepam (1.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam (1.75 or 2.5 mg orally)
Study: 6498137
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of triamcinolone acetonide
Study: 3946771
Drug: Hyoscine patch
Normalized name: HYOSCINE HYDROBROMIDE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyoscine patch applied to the skin behind one ear
Study: 3946771
Drug: Placebo patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo patch applied to the skin behind one ear
Study: 29620914
Drug: Metformin (500-850
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (500-850 mg given twice a day)
Study: 29620914
Drug: Metformin (open-label
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (open-label from week 17 to week 32)
Study: 20865841
Drug: LGP‐HA +
Approvals — FDA: no, EMA: no, PMDA: no
Description: LGP‐HA + L (Lidocaine hydrochloride 2%)
Study: 12656456
Drug: Toto ointment
Normalized name: Toto ni vavalagi oil
DrugBank: Castor oil (DB11113)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toto ointment alone
Study: 12656456
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Toto ointment and soap
Study: 12656456
Drug: Sulfur ointment
Normalized name: sulfur Topical Ointment
DrugBank: Octasulfur (DB09353)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sulfur ointment alone
Study: 6132220
Drug: Sealed catheters
Normalized name: GOLDEN SEAL
DrugBank: Goldenseal (DB16594)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sealed catheters among patients receiving systemic antibiotics
Study: 6132220
Drug: Unsealed catheters
Normalized name: CATHETER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unsealed catheters among patients receiving systemic antibiotics
Study: 29690736
Drug: Analgesic and
Normalized name: otologic analgesic and anesthetic combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesic and sedative treatment for 24 hours besides conventional treatment
Study: 29690736
Drug: Analgesic and
Normalized name: otologic analgesic and anesthetic combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesic and sedative treatment
Study: 26890974
Drug: Decaffeinated coffee
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decaffeinated coffee plus 5 mg.kg anhydrous caffeine (D + C)
Study: 26396949
Drug: Topical intranasal
Normalized name: NALOXONE RESCUE KIT INTRANASAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical intranasal corticosteroid
Study: 20577273
Drug: Standard‐fluence verteporfin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard‐fluence verteporfin photodynamic therapy (PDT) + ranibizumab
Study: 15704509
Drug: Home training
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home training with additional physical therapy
Study: 15704509
Drug: Home training
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home training without additional physical therapy
Study: 6386033
Drug: Zinc oxide
Normalized name: Zinc Oxide
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zinc oxide treatment (400 micrograms ZnO/cm2)
Study: 6386033
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (identical compress without zinc oxide)
Study: 29610765
Drug: Test implant
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test implant (modified design intended to increase primary stability)
Study: 29610765
Drug: Control implant
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control implant (standard design)
Study: 20435966
Drug: Treatment by
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment by experienced community psychotherapists
Study: 18378545
Drug: Oral glutamine
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral glutamine (30 g/day)
Study: 2217831
Drug: lipo-PGI2 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: lipo-PGI2 (2 micrograms daily for one week)
Study: 23508376
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) using green 532 nm diodes